Literature DB >> 2802553

Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254.

J Dhillon1, D A Mitchison.   

Abstract

The activities of some commonly used antituberculosis drugs were investigated within unstimulated peritoneal macrophages and in 7H-9 medium without Tween 80 using Mycobacterium microti OV254 as the target organism. In macrophage cultures, serial concentrations of isoniazid, rifampin, pyrazinamide, or streptomycin were added after a 2.5-h phagocytosis period. Viable counts were carried out at daily intervals for 5 or 6 days. The patterns of susceptibility to the four drugs were similar for M. microti and Mycobacterium tuberculosis. To ensure comparability with daily drug replacements in the macrophage experiments, the period of exposure to drugs in 7H-9 medium was kept to only 3 days. With in vitro culture at pH 6.4, drug penetration, measured as the ratio of MICs in macrophages to MICs in 7H-9 medium, was approximately 5 for isoniazid, 5 for rifampin, and 10 for streptomycin. With in vitro culture at pH 7.4, drug penetration was 100 for streptomycin, and at pH 5.6 it was 1 for pyrazinamide. Pyrazinamide was only bacteriostatic in macrophages but weakly bactericidal during the first day of exposure in vitro.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802553      PMCID: PMC172636          DOI: 10.1128/AAC.33.8.1255

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  The action of isoniazid (isonicotinic acid hydrazide) on intracellular tubercle bacilli.

Authors:  G B MACKANESS; N SMITH
Journal:  Am Rev Tuberc       Date:  1952-08

2.  Mycobacterium microti may protect itself from intracellular destruction by releasing cyclic AMP into phagosomes.

Authors:  D B Lowrie; P S Jackett; N A Ratcliffe
Journal:  Nature       Date:  1975-04-17       Impact factor: 49.962

3.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Authors:  W McDERMOTT; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-10

4.  Experimental observations on the antimycobacterial activity of rifampin.

Authors:  T F Hobby GL LENERT; J Maier-Engallena
Journal:  Proc Soc Exp Biol Med       Date:  1969-06

5.  Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations.

Authors:  R Pallanza; V Arioli; S Furesz; G Bolzoni
Journal:  Arzneimittelforschung       Date:  1967-05

6.  The penetration of rifampicin, pyrazinamide, and pyrazinoic acid into mouse macrophages.

Authors:  G Acocella; N A Carlone; A M Cuffini; G Cavallo
Journal:  Am Rev Respir Dis       Date:  1985-12

7.  Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media.

Authors:  G Middlebrook; Z Reggiardo; W D Tigertt
Journal:  Am Rev Respir Dis       Date:  1977-06

8.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.

Authors:  P D Hart; I Sutherland
Journal:  Br Med J       Date:  1977-07-30

9.  Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages.

Authors:  A J Crowle; J A Sbarbaro; M H May
Journal:  Am Rev Respir Dis       Date:  1986-11

10.  Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods.

Authors:  C N Lee; L B Heifets
Journal:  Am Rev Respir Dis       Date:  1987-08
View more
  6 in total

1.  Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.

Authors:  Helena I Boshoff; Valerie Mizrahi; Clifton E Barry
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

2.  Isoniazid could be used for antibiotic-loaded bone cement for musculoskeletal tuberculosis: an in vitro study.

Authors:  Chang Dong Han; Taegwon Oh; Sang-Nae Cho; Jae Ho Yang; Kwan Kyu Park
Journal:  Clin Orthop Relat Res       Date:  2013-03-16       Impact factor: 4.176

3.  Replication rates of Mycobacterium tuberculosis in human macrophages do not correlate with mycobacterial antibiotic susceptibility.

Authors:  Johanna Raffetseder; Elsje Pienaar; Robert Blomgran; Daniel Eklund; Veronika Patcha Brodin; Henrik Andersson; Amanda Welin; Maria Lerm
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

4.  The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB.

Authors:  Dominique Cadosch; Pia Abel Zur Wiesch; Roger Kouyos; Sebastian Bonhoeffer
Journal:  PLoS Comput Biol       Date:  2016-03-11       Impact factor: 4.475

5.  Antibiotics induce polarization of pleural macrophages to M2-like phenotype in patients with tuberculous pleuritis.

Authors:  Sisi Wang; Jian Zhang; Liyan Sui; Hao Xu; Qianling Piao; Ying Liu; Xinglong Qu; Ying Sun; Lei Song; Dan Li; Liping Peng; Shucheng Hua; Guangan Hu; Jianzhu Chen
Journal:  Sci Rep       Date:  2017-11-03       Impact factor: 4.379

6.  Determination of the activity of standard anti-tuberculosis drugs against intramacrophage Mycobacterium tuberculosis, in vitro: MGIT 960 as a viable alternative for BACTEC 460.

Authors:  Sarbjit Singh Jhamb; Amit Goyal; Prati Pal Singh
Journal:  Braz J Infect Dis       Date:  2014-04-04       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.